Adult patients with HER2-positive breast cancer that is metastatic or unresectable after receiving an anti-HER2-based treatment plan are recommended to receive trastuzumab deruxtecan (Enhertu).
The Drugs Controller General of India has already granted the company import and market permission in Form CT-20 for trastuzumab deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).
AstraZeneca Pharma India Limited’s shares were last traded at Rs. 4677.40 on the BSE, up from the previous close of Rs. 4616.00. The stock experienced an intraday high and low of 4900.00 and Rs. 4650.00, respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
